Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases

Clinica Chimica Acta

Volumn 445, Issue , 2015, Pages 155-160

  Mueller, Thomas ^a   Leitner, Isabella ^a   Egger, Margot ^a   Haltmayer, Meinhard ^a   Dieplinger, Benjamin ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cardiac troponin; Galectins; Inflammation; Interleukin 1 receptor family; Natriuretic peptides; Transforming growth factor beta superfamily

Indexed keywords

BIOLOGICAL MARKER; GALECTIN 3; GROWTH DIFFERENTIATION FACTOR 15; SOLUBLE ST2 PROTEIN; TROPONIN I; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; GALECTIN-3, HUMAN; GDF15 PROTEIN, HUMAN; IL1RL1 PROTEIN, HUMAN;

ADULT; ARTICLE; AUSTRIA; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; FEMALE; HEART FAILURE; HUMAN; MALE; PNEUMONIA; POST HOC ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEPSIS; AGED; BLOOD; CASE CONTROL STUDY; HYPERTENSION; MIDDLE AGED; PREDICTIVE VALUE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; CASE-CONTROL STUDIES; FEMALE; GALECTIN 3; GROWTH DIFFERENTIATION FACTOR 15; HEART FAILURE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PNEUMONIA; PREDICTIVE VALUE OF TESTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, CELL SURFACE; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; SEPSIS;

EID: 84927138508     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.03.033     Document Type: Article

References (31)

1. Gaggin H.K., Januzzi J.L. Biomarkers and diagnostics in HF. Biochim Biophys Acta 1832, 2013:2442-2450.
2. Schmitter D., Cotter G., Voors A.A. Clinical use of novel biomarkers in heart failure: towards personalized medicine. Heart Fail Rev 2014, 19:369-381.
3. Pouleur A.C. Which biomarkers do clinicians need for diagnosis and management of heart failure with reduced ejection fraction?. Clin Chim Acta 2015, 443:9-16.
4. Yancy C.W., Jessup M., Bozkurt B., et al. American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013, 62:e147-e239.
5. Dieplinger B., Januzzi J.L., Steinmair M., et al. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma-the Presage ST2 assay. Clin Chim Acta 2009, 409:33-40.
6. Senni M., Tribouilloy C.M., Rodeheffer R.J., et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998, 98:2282-2289.
7. Niederman M.S., Mandell L.A., Anzueto A., et al. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001, 163:1730-1754.
8. Burge S., Wedzicha J.A. COPD exacerbations: definitions and classifications. Eur Respir J 2003, 21:46S-53S.
9. Levey A.S., Eckardt K.U., Tsukamoto Y., et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005, 67:2089-2100.
10. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992, 20:864-874.
11. La'ulu S.L., Apple F.S., Murakami M.M., Ler R., Roberts W.L., Straseski J.A. Performance characteristics of the ARCHITECT galectin-3 assay. Clin Biochem 2013, 46:119-122.
12. Standards Institute Laborator Clinical Evaluation of precision performance of clinical chemistry devices; approved guideline. CLSI Document EP5-A 1999, CLSI, Wayne, PA.
13. Bessière F., Khenifer S., Dubourg J., Durieu I., Lega J.C. Prognostic value of troponins in sepsis: a meta-analysis. Intensive Care Med 2013, 39:1181-1189.
14. Liew F.Y., Pitman N.I., McInnes I.B. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 2010, 10:103-110.
15. Villarreal D.O., Weiner D.B. Interleukin 33: a switch-hitting cytokine. Curr Opin Immunol 2014, 28C:102-106.
16. Mueller T., Jaffe A.S. Soluble ST2 - analytical considerations. Am J Cardiol 2015, 115(7S):8B-21B.
17. Dieplinger B., Mueller T. Soluble ST2 in heart failure. Clin Chim Acta 2015, 443C:57-70.
18. Henderson N.C., Sethi T. The regulation of inflammation by galectin-3. Immunol Rev 2009, 230:160-171.
19. Gao P., Simpson J.L., Zhang J., Gibson P.G. Galectin-3: its role in asthma and potential as an anti-inflammatory target. Respir Res 2013, 14:136.
20. Song L., Tang J.W., Owusu L., Sun M.Z., Wu J., Zhang J. Galectin-3 in cancer. Clin Chim Acta 2014, 431:185-191.
21. Ravani P., Barrett B.J. Galectin-3 and new-onset CKD: marker or mediator?. J Am Soc Nephrol 2013, 24:1342-1344.
22. Corre J., Hébraud B., Bourin P. Concise review: growth differentiation factor 15 in pathology: a clinical role?. Stem Cells Transl Med 2013, 2:946-952.
23. Lindahl B. The story of growth differentiation factor 15: another piece of the puzzle. Clin Chem 2013, 59:1550-1552.
24. Mimeault M., Batra S.K. Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. J Cell Physiol 2010, 224:626-635.
25. Kempf T., Wollert K.C. Risk stratification in critically ill patients: GDF-15 scores in adult respiratory distress syndrome. Crit Care 2013, 17:173.
26. Wollert K.C., Kempf T. Growth differentiation factor 15 in heart failure: an update. Curr Heart Fail Rep 2012, 9:337-345.
27. Unsicker K., Spittau B., Krieglstein K. The multiple facets of the TGF-β family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1. Cytokine Growth Factor Rev 2013, 24:373-384.
28. Dieplinger B., Gegenhuber A., Kaar G., Poelz W., Haltmayer M., Mueller T. Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department. Clin Biochem 2010, 43:714-719.
29. Thomsen R.W., Kasatpibal N., Riis A., Nørgaard M., Sørensen H.T. The impact of pre-existing heart failure on pneumonia prognosis: population-based cohort study. J Gen Intern Med 2008, 23:1407-1413.
30. Macchia A., Monte S., Romero M., D'Ettorre A., Tognoni G. The prognostic influence of chronic obstructive pulmonary disease in patients hospitalised for chronic heart failure. Eur J Heart Fail 2007, 9:942-948.
31. Ho J.E., Mahajan A., Chen M.H., et al. Clinical and genetic correlates of growth differentiation factor 15 in the community. Clin Chem 2012, 58:1582-1591.